Daiichi Sankyo Company, Limited (TYO:4568)
2,953.00
+73.00 (2.53%)
Sep 25, 2026, 10:45 AM JST
Daiichi Sankyo Company Employees
Daiichi Sankyo Company had 20,171 employees as of March 31, 2026. The number of employees increased by 406 or 2.05% compared to the previous year.
Employees
20,171
Change (1Y)
406
Growth (1Y)
2.05%
Revenue / Employee
110.22M JPY
Profits / Employee
13.03M JPY
Market Cap
5.24T
Employees Chart
| Date | Employees | Change (1Y) | Growth (1Y) |
|---|---|---|---|
| Mar 31, 2026 | 20,171 | 406 | 2.05% |
| Mar 31, 2025 | 19,765 | 1,039 | 5.55% |
| Mar 31, 2024 | 18,726 | 1,291 | 7.40% |
| Mar 31, 2023 | 17,435 | 977 | 5.94% |
| Mar 31, 2022 | 16,458 | 425 | 2.65% |
| Mar 31, 2021 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Mar 31, 2020 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Mar 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Mar 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Mar 31, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Related Stocks
| Company Name | Employees |
|---|---|
| Takeda Pharmaceutical Company | 47,029 |
| Otsuka Holdings | 37,758 |
| HOYA Corporation | 37,752 |
| Olympus | 28,138 |
| M3, Inc. | 17,010 |
| Astellas Pharma | 14,099 |
| Eisai | 10,543 |
| Shionogi & | 6,223 |
Daiichi Sankyo Company News
- 15 hours ago - Malaysia's IHH's unit appeals Tokyo court's rejection of Daiichi Sankyo damages claim - Reuters
- 3 days ago - AstraZeneca: CHMP Recommends Enhertu For Approval In The EU - Nasdaq
- 6 days ago - Daiichi Sankyo Gets Japan Approval For Enhertu, Datroway In First-Line Metastatic Breast Cancer - Nasdaq
- 7 days ago - AstraZeneca's Enhertu Gets NICE Recommendation For HER2 Low Metastatic Breast Cancer - Nasdaq
- 7 days ago - Fortis moves Supreme Court against Delhi High Court order - The Times of India
- 10 days ago - AstraZeneca's Enhertu Improves PFS By 6 Months In First-Line HER2-Mutant NSCLC; Daiichi Stock Up - Nasdaq
- 14 days ago - Malaysia's IHH's unit loses Tokyo court case against Daiichi Sankyo over Fortis deal - Reuters
- 23 days ago - AstraZeneca And Daiichi Sankyo Gain EU Nod For Enhertu Plus Pertuzumab In HER2+ Breast Cancer - Nasdaq